clear cell adenocarcinoma
clear cell adenocarcinoma
Explore linked clinical trials. Standard reference: MONDO:000500411 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-09-16 | NCT07718854 | |
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, endocrine system disorder, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma | Active, not recruiting | Phase 2 | 2026-08-20 | NCT03355976 | |
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, endocrine system disorder, epithelial neoplasm, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma | Recruiting | Phase 2 | 2026-07-27 | NCT05460000 | |
| Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell adenocarcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, urinary system disorder | Active, not recruiting | Not applicable | 2026-07-08 | NCT01582204 | |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, carcinoma, cervix disorder, clear cell adenocarcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, uterine disorder, vaginal cancer, vaginal disorder, vulva cancer, vulvar disease | Recruiting | Phase 2 | 2026-05-06 | NCT06023862 | |
| Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, clear cell adenocarcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 1 | 2026-04-29 | NCT07072234 | |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Sex Cord-Gonadal Stromal Tumors, adenocarcinoma, carcinoma, carcinosarcoma, clear cell adenocarcinoma, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastrointestinal stromal tumor, germinoma, glioma, gonadal tissue neoplasm, mixed neoplasm, neoplasm, neuroendocrine neoplasm, neuroepithelial neoplasm, ovarian germ cell tumor, ovarian mucinous adenocarcinoma, ovarian serous tumor, primitive neuroectodermal tumor, sarcoma, seminoma, small cell carcinoma | Recruiting | Phase 2 | 2026-03-18 | NCT05500391 | |
| An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, chromophobe renal cell carcinoma, clear cell adenocarcinoma, epithelial neoplasm, fumaric aciduria, hereditary leiomyomatosis and renal cell cancer, kidney cancer, kidney disorder, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, transitional cell carcinoma, urinary system disorder, urothelial carcinoma | Recruiting | Not applicable | 2026-01-28 | NCT04623502 | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | Adnexal Diseases, Anal Cancer, Carcinoma, Ovarian Epithelial, Carcinoma, Thymic, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Thymus Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, adenoma, anus disorder, anus neoplasm, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, clear cell adenocarcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, cutaneous melanoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, head and neck squamous cell carcinoma, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, lymphatic system disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, mesothelial neoplasm, mesothelioma, mixed neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, otorhinolaryngologic disease, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, rectal disorder, rectal neoplasm, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, thymoma, triple-negative breast carcinoma, urinary system disorder | Active, not recruiting | Phase 1 | 2026-01-06 | NCT05544929 | |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, clear cell adenocarcinoma, connective tissue neoplasm, cystic, mucinous, and serous neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, mucinous adenocarcinoma, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian clear cell malignant adenofibroma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian seromucinous carcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, undifferentiated carcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 3 | 2025-12-30 | NCT00565851 | |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, carcinoma, cervical carcinoma, cervix disorder, clear cell adenocarcinoma, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, prostate cancer, prostate disorder, uterine disorder | Active, not recruiting | Phase 2 | 2025-02-07 | NCT05032040 |